2 results
Approved WMOCompleted
To gain more knowledge about the effects of SGLT2 inhibition on renal hemodynamics and the underlying mechanisms.
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.